Hugo Villanueva

Hugo Villanueva

Auto-generated profile, based on publicly available information

Hugo Villanueva

Baylor College of Medicine 7 Advanced Cell Engineering and 3D Models Core, Department of Biochemistry and Molecular Biology Houston, Texas

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
AVAvani Vyas
Avani Vyas
RGRoberto Gomez
Roberto Gomez
SCSilvia Cruz-Rangel
Silvia Cruz-Rangel
HVHugo Villanueva
Hugo Villanueva
ASAndrew G. Sikora
Andrew G. Sikora
UDUmamaheswar Duvvuri
Umamaheswar Duvvuri
Significance: Cisplatin is the first line therapy for patients with head and neck cancer. However, resistance to cisplatin remains a major concern. High expression of the calcium-activated chloride channel TMEM16A in tumors portends poor survival in these patients, possibly because of drug resistance. Here, we show that TMEM16A drives the sequestration of cisplatin into lysosomes. Subsequently, cisplatin is expelled via the delivery of lysosomes to the cell surface. We show that TMEM16A enhances this process, thereby promoting cisplatin resistance. We also show that lysosomal inhibition synergizes with cisplatin to induce tumor cell death. Our data uncovers a new fundamental feature of both lysosomal physiology and cancer cell biology that can potentially impact the treatment of patients with head and neck cancer.

24 December 2022 in Heliyon
Verified
Journal Article
Open access
HVHugo Villanueva
Hugo Villanueva
GWGabrielle A. Wells
Gabrielle A. Wells
MMMalachi T. Miller
Malachi T. Miller
MVMariana Villanueva
Mariana Villanueva
RPRavi Pathak
Ravi Pathak
SLSeth P Lerner
Seth P Lerner
Non-metastatic muscle invasive urothelial bladder cancer (MIBC) has a poor prognosis and standard of care (SOC) includes neoadjuvant cisplatin-based chemotherapy (NAC) combined with cystectomy. Patients receiving NAC have at best <10% improvement in five-year overall survival compared to cystectomy alone. This major clinical problem underscores gaps in our understanding of resistance mechanisms and a need for reliable pre-clinical models. The chicken embryo chorioallantoic membrane (CAM) represents a rapid, scalable, and cost-effective alternative to immunocompromised mice for establishing patient-derived xenografts (PDX) in vivo. CAM-PDX leverages an easily accessible engraftment scaffold and vascular-rich, immunosuppressed environment for the engraftment of PDX tumors and subsequent functional studies. We optimized engraftment conditions for primary MIBC tumors using the CAM-PDX model and tested concordance between cisplatin-based chemotherapy response of patients to matching PDX tumors using tumor growth coupled with immunohistochemistry markers of proliferation and apoptosis. We also tested select kinase inhibitor response on chemotherapy-resistant bladder cancers on the CAM-PDX using tumor growth measurements and immuno-detection of proliferation marker, Ki-67. Our results show primary, NAC-resistant, MIBC tumors grown on the CAM share histological characteristics along with cisplatin-based chemotherapy resistance observed in the clinic for matched parent human tumor specimens. Patient tumor specimens acquired after chemotherapy treatment (post-NAC) and exhibiting NAC resistance were engrafted successfully on the CAM and displayed decreased tumor growth size and proliferation in response to treatment with a dual EGFR and HER2 inhibitor, but had no significant response to either CDK4/6 or FGFR inhibition. Our data suggests concordance between cisplatin-based chemotherapy resistance phenotypes in primary patient tumors and CAM-PDX models. Further, proteogenomic informed kinase inhibitor use on MIBC CAM-PDX models suggests a benefit from integration of rapid in vivo testing of novel therapeutics to inform more complex, pre-clinical mouse PDX experiments for more effective clinical trial design aimed at achieving optimal precision medicine for patients with limited treatment options.

3 August 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
AHAnh Minh Tran Huynh
Anh Minh Tran Huynh
JLJonathan T. Lei
Jonathan T. Lei
RBRachel Brough
Rachel Brough
CSChristina Sallas
Christina Sallas
JXJun Xu
Jun Xu
MAMeenakshi Anurag
Meenakshi Anurag
Proteogenomic analyses have identified an association between LIG1 (DNA ligase I) loss and chemotherapy resistance in a subset of triple-negative breast cancer (TNBC) enriched for TP53 mutations. In this study, we demonstrate that co-occurrence of TP53 mutations and LIG1 loss is associated with upregulated DNA damage repair (DDR) activity, including homologous recombination (HR), likely contributing to reduced platinum sensitivity. Unbiased genetic and monotherapy drug screens identified poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) as a potential treatment for LIG1-depleted tumors; however, the increase in sensitivity was modest and lower than that observed in TNBC models with HR deficiency. Subsequently, a screen of PARP inhibition in combination with each of 120 clinically relevant DDR inhibitors revealed that PARPi sensitivity in LIG1-loss cells was significantly enhanced by the addition of an ATR inhibitor. Olaparib and ceralasertib demonstrated synergistic cytotoxicity in LIG1-loss cell line models; the combination significantly reduced tumor volume in a LIG1-low patient-derived xenograft (PDX )model compared with either monotherapy and showed greater ex vivo cytotoxicity in a LIG1-low PDX organoid model versus a LIG1-high control. Hence, this study highlights LIG1 status as a stratification factor for ongoing and future clinical trials of DDR-targeted combinations in TNBCs.

5 May 2026 in Cancer Letters
Verified
Journal Article
Closed access
CAChandra Sekhar Amara
Chandra Sekhar Amara
DPDanthasinghe Waduge Badrajee Piyarathna
Danthasinghe Waduge Badrajee Piyarathna
AKAbu Hena Mostafa Kamal
Abu Hena Mostafa Kamal
YCYuen San Chan
Yuen San Chan
KRKarthik Reddy Kami Reddy
Karthik Reddy Kami Reddy
Nagireddy PutluriNagireddy Putluri
Nagireddy Putluri